Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Inovio Pharmaceuticals Jumped 18% Today

By Brian Orelli, PhD – Apr 22, 2020 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Jim Cramer called out the vaccine maker.

What happened

Shares of Inovio Pharmaceuticals (INO -2.19%) closed up 18% on Wenesday after Jim Cramer gave the vaccine maker a shout-out on his Mad Money show yesterday. Fellow COVID-19 vaccine-maker Moderna Pharmaceuticals (MRNA -0.04%) closed up 4% on the day. https://www.thestreet.com/jim-cramer/oil-rout-spooks-stocks-cramers-mad-money-april-21

So what

Inovio is developing a COVID-19 vaccine called INO-4800 that entered a phase 1 clinical trial earlier this month. Data from Inovio's study is expected by late summer, so it isn't readily apparent why investors would be buying today other than Cramer's call-out. Moderna is a little ahead of Inovio, so it should have data before Inovio.

Inovio and Moderna were able to develop their vaccines quicker than the large pharmaceutical companies, such as Johnson & Johnson (JNJ -0.31%), which won't start a clinical trial until September, because their vaccines use patients' cells to express the protein vaccine, eliminating the need for developing a new manufacturing system like Johnson & Johnson. Inovio's vaccine uses DNA to express the protein, while Moderna's mRNA-1273 uses RNA.

Gloved hands about to give an injection into a shoulder

Image source: Getty Images.

Now what

At a market cap of $1.7 billion, Inovio isn't particularly expensive if the biotech is able to keep pace with Moderna and show that INO-4800 can induce an immune response.

But investors should keep in mind that investing in Inovio is still risky. There are no guarantees that the vaccine will create antibodies that protect patients. And estimating exactly how much of the vaccine Inovio will be able to sell is difficult without knowing the price, how much it'll be able to manufacture, and how much competition INO-4800 will have if regulators approve it.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
INO
$1.79 (-2.19%) $0.04
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.11 (-0.31%) $0.51
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$125.62 (-0.04%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.